title: Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
abstract: BACKGROUND
  Since June 2012, the has been a worldwide lack of available of the Connaught strain. In December 2012, a group of experts met in the Spanish Association of Urology to analyze this situation and propose alternatives.
  
  
  OBJECTIVE
  To present the work performed by said committee and the resulting recommendations.
  
  
  METHODS
  An update has been made of the principal existing evidence in the treatment of middle and high risk tumors. Special mention has been made regarding the those related with the use of BCG and their possible alternative due to the different availability of BCG.
  
  
  RESULTS
  In tumors with high risk of progression, immediate cystectomy should be considered when BCG is not available, with dose reduction or alternating with chemotherapy as methods to economize on the use of BCG when availability is reduced. In tumors having middle risk of progression, chemotherapy can be used, although when it is associated to a high risk of relapse, BCG would be indicated if available with the mentioned savings guidelines. BCG requires maintenance to maintain its effectiveness, it being necessary to optimize the application of endovesical chemotherapy and to use systems that increase its penetration into the bladder wall (EMDA) if they are available.
  
  
  CONCLUSIONS
  Due to the scarcity of BCG, it has been necessary to agree on a series of recommendations that have been published on the web page of the Spanish Association of Urology.
authors.affiliation: Servicio de Urología, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, España. Electronic address: jmfernandezgomez23@gmail.com.
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández-Gómez
authors.forename: J
authors.initials: J
authors.lastname: Carballido-Rodríguez
authors.forename: J M
authors.initials: JM
authors.lastname: Cozar-Olmo
authors.forename: J
authors.initials: J
authors.lastname: Palou-Redorta
authors.forename: E
authors.initials: E
authors.lastname: Solsona-Narbón
authors.forename: J M
authors.initials: JM
authors.lastname: Unda-Urzaiz
mesh_terms: D000283:Administration, Intravesical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015653:Cystectomy; D018450:Disease Progression; D004306:Dose-Response Relationship, Immunologic; D015251:Epirubicin / Q000008:administration & dosage; D006801:Humans; D016233:Immunotherapy, Active; D007322:Instillation, Drug; D016685:Mitomycin / Q000008:administration & dosage; D009163:Mycobacterium bovis / Q000145:classification / Q000276:immunology; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control; D012074:Remission Induction; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery* / Q000628:therapy
chemical_list: D001500:BCG Vaccine; D015251:Epirubicin; D016685:Mitomycin
keywords: Bacillus Calmette-Guerin; Bacilo Calmette-Guerin; Bladder cancer; Cistectomía; Cystectomy; Cáncer de vejiga; Intravesical therapy; Maintenance; Mantenimiento; Terapia intravesical